Expert Interview
Discussing commercial use of Filspari (sparsentan) and Vanrafia (atrasentan) in IgAN
Ticker(s): TVTX, NVSInstitution: Montefiore
- Medical Director, Pediatric Nephrology at Montefiore Health System, Inc., Associate Professor of Pediatrics at the Albert Einstein College of Medicine & Visiting Assistant Professor at Rockefeller University.
- Clinical interests are polycystic kidney disease, lupus nephritis, genetic causes of stone disease, complement pathway defects, immune-mediated renal diseases (autoimmune and secondary immune disorders) and biomarkers of acute kidney injury with a research interest is in lupus nephritis.
- Involved in clinical and translational research studying factors leading to progression to end-stage kidney disease, including fibrosis and complement-mediated pathways in lupus nephritis.
How many patients do you have on Filspari?
Added By: wilson_adminHow do you think you will use Vanrafia going forward?
Added By: wilson_adminHow important are these medications in IgAN relative to what was available prior to their approvals?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
